About: Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertake research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.79 (+4.68%)
PPCB NASDAQ Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc. Common Stock share price
Atividade de preço de PPCB
Último preço
$ 1,790
Variação (24h)
0,08 USD (4,68%)
Volume
15.68K
Volume (média 4 sem.)
-
Abertura
$ 1,77
Variação do dia
$ 1,76 - $ 1,85
Fechamento anterior
$ 1,71
Último negócio
04 Nov, 9:11 pm GMT+0
Atrasado
04 Nov, 9:11 pm GMT+0
PPCB price performance
Atrasado
04 Nov, 9:11 pm GMT+0
PPCB details
quote.marketSignals